Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study

Fertility and Sterility

Volumn 90, Issue 3, 2008, Pages 727-730

  Zolghadri, Jaleh ^a   Tavana, Zohreh ^a   Kazerooni, Talie ^a   Soveid, Mahmoud ^a   Taghieh, Marzieh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

abnormal glucose tolerance test; metformin; Recurrent abortion

Indexed keywords

METFORMIN; PLACEBO;

ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; SPONTANEOUS ABORTION;

ABORTION, HABITUAL; ADOLESCENT; ADULT; COMORBIDITY; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; IRAN; METFORMIN; PREGNANCY; PREGNANCY OUTCOME; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 51449106596     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.06.079     Document Type: Article

References (22)

1. Prport C.P., and Murphy A.A. Endocrinopathies associated with recurrent pregnancy loss. Semin Reprod Med 18 (2000) 357-362
2. Fedele L., and Bianchi S. Habitual abortion: endocrinological aspects. Curr Opin Obstet Gynecol 7 (1995) 351-356
3. Saad F.A., and Jauniaux E. Recurrent early pregnancy loss and consanguinity. Rep Biomed Online 5 (2002) 167-170
4. Crane J.P., and Wahl N. The role of maternal diabetes in repetitive spontaneous abortion. Fertil Steril 36 (1981) 477-479
5. Coulam C.B., and Stern J.J. Endocrine factors associated with recurrent spontaneous abortion. Clin Obstet Gynecol 37 (1994) 730-734
6. Carrington B., Sacks G., and Regan L. Recurrent miscarriage pathophysiology and outcome. Curr Opin Obstet Gynecol 17 (2005) 591-597
7. Catrington B., Sacks G., and Regan L. Recurrent miscarriage: pathophysiology and outcome. Curr Opin Obstet Gynecol 17 (2005) 591-597
8. Latasha B., Craig M.O., Raymond W., Williams M.H., and Katten. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 78 (2002) 487-489
9. Sutherland H.W., and Fisher P.M. Fetal loss and maternal glucose intolerance. A retrospective study. Padia-pradol 17 (1982) 279-286
10. Yong E.H., Sun N.M., and Ho P.C. Effects of metformin on ovulation rate, hormonal and metabolic profile in women with clomiphene-resistant polycystic ovaries: a randomized double-blinded placebo-controlled trial. Hum Reprod 16 (2001) 1625-1631
11. Glueck C.J., Sherif G., Awadella M.O., and Harvey P.H. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos and miscarriage. Fertil Steril 74 (2000) 394-397
12. Regan L., Owen E.J., and Jacob H.S. Hypersecretion of luteinizing hormone infertility and miscarriage. Lancet 336 (1990) 1141-1144
13. Glueck C.J., and Harvey P.H. Dancameron. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first trimester spontaneous abortion, a pilot study. Fertil Steril 75 (2001) 46-52
14. Glueck C.J., Wang P., Goldenberg N., and Smith L.S. Pregnancy outcome among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17 (2002) 2858-2864
15. Jakubowicz D.J., Iuorno M.J., and Salmon J. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clinic Endocrinol 87 (2002) 524-529
16. Palomba S., Falbo A., Otio Jr. F., Russo T., Tolino A., and Zullo F. Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. Fertil Steril 85 (2006) 1511
17. Glueck C.J., Wang P., Goldenberg N., and Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis enoxaparin, metformin. Clin Appl Thromb Hemost 10 (2004) 323-334
18. Jakubowicz D.J., Seppalam, and Jakubowicz S. Metformin increases luteal phase, serum glycodelin and insulin-like growth factor-binding protein-1 concentrations and enhances uterine vascularity and enhances uterine blood follow in the polycystic ovary syndrome. J Clin Endocrinol Metab 86 (2001) 1126-1133
19. Atiomo W.U., Bates S.A., Condon J.E., Shaw S., West J.N., and Prentice A.G. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 236-241
20. Sampson M., Kong C., Patel A., Unwin R., and Jacobs H.S. Ambulatory blood pressure profile and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 45 (1996) 623-629
21. Glueck C.J., Wang P., Fontine R.N., Sieve L., and Smith L.S. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 48 (1999) 1589-1595
22. Gris J.C., Neveo S., Maru P., Biron C., Medon B., and Schred J.F. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 122 (1993) 606-615